Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center
| Autor: | Nelly G. Adel, L Reich, Melissa Pozotrigo, Elyn Riedel, Hani Hassoun, Nikoletta Lendvai, Xiaoshe Chen, Alexander M. Lesokhin, Sergio Giralt, David J. Chung, Danielle Chimento, Raymond L. Comenzo, Heather Landau |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Population Internal medicine Granulocyte Colony-Stimulating Factor medicine Humans Treatment Failure Progenitor cell education Cyclophosphamide Lenalidomide Multiple myeloma Aged Retrospective Studies Transplantation education.field_of_study Bortezomib business.industry Data Collection Age Factors Hematology Middle Aged medicine.disease Hematopoietic Stem Cell Mobilization Thalidomide Treatment Outcome Multivariate Analysis Practice Guidelines as Topic Immunology Female Stem cell Multiple Myeloma business medicine.drug |
| Zdroj: | Bone Marrow Transplantation. 48:1033-1039 |
| ISSN: | 1476-5365 0268-3369 |
| DOI: | 10.1038/bmt.2012.281 |
| Popis: | Thalidomide, lenalidomide and bortezomib have increasingly been incorporated in first-line induction therapies for multiple myeloma. Concerns regarding the impact of these agents, especially lenalidomide, on stem cell mobilization prompted us to re-evaluate the risk factors that impact mobilization, including exposure to novel induction regimens. Among 317 patients who proceeded to stem cell collection after induction therapy between 2000 and 2009, the rate of mobilization failure, defined as the inability to collect 5 × 10(6) CD34+ cells/kg following the first collection attempt, was 13%. By multivariate analysis, independent risk factors associated with mobilization failure included older age (P=0.04), lower platelet count (P=0.002) and use of single-agent G-CSF for mobilization (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|